Iron indices and intravenous ferumoxytol: Time to steady-state;Indicateurs du fer et ferumoxytol par voie intraveineuse: Temps pour atteindre l'état d'équilibre

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1308-1314

  Kapoian, Toros ^a   O'Mara, Neeta Bahal ^b   Carreon, Myra ^c   Gajary, Amelia ^b   Rizkala, Adel ^d   Lefavour, Gertrude ^e   Sherman, Richard A ^e   Walker, John ^e  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Dialysis Clinics Inc   (United States)

^c Kidney Disease Consultants   (United States)

^d Dialysis Clin ic Inc ^*

^e RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anemia; Hemodialysis; Intravenous iron; Relative iron deficiency

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY TEMPERATURE MEASUREMENT; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG INDUCED HEADACHE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; IRON DEFICIENCY; LABORATORY TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCLE CRAMP; PATIENT MONITORING; PRIORITY JOURNAL; PULSE RATE; SCREENING TEST; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TRANSFERRIN SATURATION; TREATMENT DURATION; VITAL SIGN;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; C-REACTIVE PROTEIN; FEMALE; FERRITINS; FERUMOXYTOL; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; RENAL DIALYSIS; TRANSFERRIN;

EID: 84867792959     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q614     Document Type: Article

References (19)

1. Kaufman JS, Reda DJ, Fye CL, et al. Diagnostic value of iron indices in hemodialysis subjects receiving epoetin. Kidney Int 2001;60:300-8.
2. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(suppl 3):S1-S146.
3. Raimundo M, Abreu F, Gomes da Costa A. Parenteral iron safety in haemodialysis subjects. Port J Nephrol Hypert 2009;23:153-9.
4. Schiesser D, Binet I, Tsinalis D, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin re-quirement in iron-replete haemodialysis subjects. Nephrol Dial Transpl 2006;21: 2841-5.
5. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium fer-ric gluconate complex in sucrose is safe and effective in hemodialysis subjects: North American clinical trial. Am J Kidney Dis 1999;33:471-82.
6. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJM. Iron absorption in erythropoietin-treated haemodialysis subjects: effects of iron availability, inflammation, and alu-minum. Nephrol Dial Transpl 1998;13:82-8.
7. Pollak VE, Lorch JA, Shukla R, Satwah S. The importance of iron in long-term survival of maintenance hemodialysis subjects treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol 2009;10. doi:10.1186/1471-2369-10-6.
8. Macdougall I. Intravenous administration of iron in epoetin-treated haemodialysis subjects-which drugs, which regimen? Nephrol Dial Transpl 2000;15:1743-5.
9. Ferumoxytol approval letter to AMAG Pharmaceuticals, Inc. Rockville, MD: Food and Drug Administration, June 30, 2009.
10. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-605.
11. Product information. Ferumoxytol (ferumoxytol). Lexington, MA: AMAG Pharmaceuticals, Inc., November 2011.
12. AMCP formulary submission dossier: Feraheme. A phase III study of the safety and efficacy of Feraheme (compared with oral iron) as an iron replacement therapy in chronic kidney disease patients not on dialysis. Lexington, MA: AMAG Pharmaceuticals Inc., 2009.
13. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJG. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:386-93.
14. Fishbane S, Kalantar-Zadeh K, Nissenson AR. Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 2004;17:336-41.
15. Bralow S. Insights into achieving target hemoglobin levels: increasing the serum ferritin parameter. Dial Transplant 2009;5:1-6.
16. Product information. Ferrlecit (ferric gluconate). Bridgewater, NJ: Sanofi-Aventis, 2011.
17. Product information. Venofer (iron sucrose). Shirley, NY: American Re-gent, Inc., June 2011.
18. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis subjects. Am J Nephrol 1999;34:21-8.
19. Product information. INFeD (iron dextran). Corona, CA: Watson Phar-maceuticals, Inc., August 2009.